Trial reportVeterinary dermatology2013
Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis.
Trial report in Veterinary dermatology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 127 citations in OpenAlex.
- Repeated oral dose tolerance in dogs treated concomitantly with ciclosporin and oclacitinib for three weeks.Veterinary dermatology · 2016Trial
- A blinded, randomized clinical trial comparing the efficacy and safety of oclacitinib and ciclosporin for the control of atopic dermatitis in client-owned dogs.Veterinary dermatology · 2015Trial
- Efficacy of oclacitinib (Apoquel®) compared with prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in client-owned dogs in Australia.Veterinary dermatology · 2014Trial
- A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel®) in client-owned dogs with atopic dermatitis.Veterinary dermatology · 2013Trial
- Oclacitinib for Controlling Pruritus and Associated Skin Lesions in 16 Horses With Allergic Dermatitis.Veterinary dermatology · 2026Article
- Treatment-Associated Differences in Serum Cytokine Profiles in Canine Atopic Dermatitis: A Cross-Sectional Study.Animals : an open access journal from MDPI · 2026Article
- A Retrospective Case Series Reporting the Clinical Efficacy and Adverse Events of Oclacitinib Administration for Skin Disease in 238 Cats.Veterinary dermatology · 2026Article
- Some of the Newest Therapeutic Methods in Canine Atopic Dermatitis.Veterinary sciences · 2026Review
- Cutaneous plasmacytosis with atypical clinical behavior in two dogs.The Journal of veterinary medical science · 2026Article
- Efficacy and Field Safety of Ilunocitinib for the Control of Allergic Dermatitis in Client-Owned Dogs: A Multicenter, Double-Masked, Randomised, Placebo-Controlled Clinical Trial.Veterinary dermatology · 2025Article
- Anti-Cytokine Drugs in the Treatment of Canine Atopic Dermatitis.International journal of molecular sciences · 2025Review
- Drug Repurposing in Veterinary Oncology: Myth or Reality?Veterinary sciences · 2025Review
- Efficacy and field safety of ilunocitinib for the control of atopic dermatitis in client-owned dogs: A multicentre, double-masked, randomised, placebo-controlled clinical trial.Veterinary dermatology · 2025Article
- Long-term oclacitinib administration for the control of feline allergic pruritus: A retrospective study of 14 client-owned cats.The Canadian veterinary journal = La revue veterinaire canadienne · 2025Article
- Exercise-induced mild rhabdomyolysis associated with oclacitinib in a dog.The Journal of veterinary medical science · 2025Article
- Safety of the Selective JAK1 Inhibitor Oclacitinib in Dogs.Journal of veterinary pharmacology and therapeutics · 2025Review
- Long term use of lokivetmab (Cytopoint®) in atopic dogs.BMC veterinary research · 2025Article
- Enhancement of radio-sensitivity by inhibition of Janus kinase signaling with oclacitinib in canine tumor cell lines.Molecular therapy. Oncology · 2025Article
- Use of Oclacitinib in the treatment of pemphigus foliaceus in a dog: case report.Brazilian journal of veterinary medicine · 2025Article
- JAK3 inhibitor suppresses multipotent ILC2s and attenuates steroid-resistant asthma.Science advances · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOclacitinib (Apoquel(®) ) inhibits the function of a variety of pro-inflammatory, pro-allergic and pruritogenic cytokines that are dependent on Janus kinase enzyme activity. Oclacitinib selectively inhibits Janus kinase 1. HYPOTHESIS/
objectivesWe aimed to evaluate the safety and efficacy of oclacitinib for the control of pruritus associated with allergic dermatitis in a randomized, double-blinded, placebo-controlled trial.
methodsClient-owned dogs (n = 436) with moderate to severe owner-assessed pruritus and a presumptive diagnosis of allergic dermatitis were enrolled. Dogs were randomized to either oclacitinib at 0.4-0.6 mg/kg orally twice daily or an excipient-matched placebo. An enhanced 10 cm visual analog scale (VAS) was used by the owners to assess the severity of pruritus from day 0 to 7 and by veterinarians to assess the severity of dermatitis on days 0 and 7. Dogs could remain on the study for 28 days.
resultsPretreatment owner and veterinary VAS scores were similar for the two treatment groups. Oclacitinib produced a rapid onset of efficacy within 24 h. Mean oclacitinib Owner Pruritus VAS scores were significantly better than placebo scores (P < 0.0001) on each assessment day. Pruritus scores decreased from 7.58 to 2.59 cm following oclacitinib treatment. The day 7 mean oclacitinib Veterinarian Dermatitis VAS scores were also significantly better (P < 0.0001) than placebo scores. Diarrhoea and vomiting were reported with similar frequency in both groups. CONCLUSIONS AND CLINICAL IMPORTANCE: In this study, oclacitinib provided rapid, effective and safe control of pruritus associated with allergic dermatitis, with owners and veterinarians noting substantial improvements in pruritus and dermatitis VAS scores.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.